RTI Biologics
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), RTI Biologics met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share was unchanged.
Gross margins grew, operating margins increased, net margins contracted.
Revenue details
RTI Biologics logged revenue of $44.6 million. The eight analysts polled by S&P Capital IQ anticipated revenue of $44.2 million on the same basis. GAAP reported sales were 5.5% higher than the prior-year quarter's $42.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $0.05. The eight earnings estimates compiled by S&P Capital IQ averaged $0.04 per share. GAAP EPS of $0.05 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 48.7%, 300 basis points better than the prior-year quarter. Operating margin was 9.2%, 170 basis points better than the prior-year quarter. Net margin was 6.3%, 20 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $45.7 million. On the bottom line, the average EPS estimate is $0.05.
Next year's average estimate for revenue is $178.9 million. The average EPS estimate is $0.17.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 209 members out of 219 rating the stock outperform, and 10 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give RTI Biologics a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.62.
- Add RTI Biologics to My Watchlist.
